Skip to main content

Table 1 DOX-induced LV dysfunction and remodeling after 12 weeks chronic treatment is greater in sGCα1-/- than WT mice:

From: Cardiac soluble guanylate cyclase protects against the cardiac dysfunction induced by chronic doxorubicin treatment in mice

Echocardiography WT + saline (n=7) sGCα1-/- + saline (n=6) WT + DOX (n=12) sGCα1-/- + DOX (n=11)
LVIDS (mm) 1.3±0.1 1.3±0.0 1.7±0.1† 2.0±0.1†*
LVIDD (mm) 3.0±0.0 3.0±0.0 3.2±0.1† 3.3±0.0†
FS (%) 57±1 57±1 48±2† 40±1†*
HR (bpm) 531±13 505±18 428±17† 426±18†
Hemodynamic measurements WT + saline (n=6) sGCα1-/- + saline (n=5) WT + DOX (n=12) sGCα1-/- + DOX (n=9)
ESV (μl) 19±1 19±1 26±3† 37±3†*
EDV (μl) 43±2 41±2 51±2† 58±2†*
EF (%) 60±2 58±3 55±4 42±3†*
dP/dtmax (mmHg/s) 13,499±1,433 11,995±601 13,503±678 10,386±875*
dP/dtmin (mmHg/s) -12,053±1,809 -11,420±950 -13,531±846 -10,943±940¶
Tau (ms) 5.1±0.1 4.9±0.2 5.6±0.2† 6.3±0.3†¶
PRSW 83±9 84±6 70±9 49±7†¶
Ees (mmHg/μl) 6.3±1.2 7.3±1.4 4.0±0.8† 2.3±0.3†¶
EDPVR (mmHg/μl) 0.21±0.03 0.18±0.02 0.16±0.02 0.19±0.02
HR (bpm) 576±8 614±12 528±9† 530±14†*
  1. LVIDS indicates left ventricular internal diameter at end-systole; LVIDD, left ventricular internal diameter at end-diastole; FS, fractional shortening; HR, heart rate; ESV, end-systolic volume; EDV, end-diastolic volume; EF, ejection fraction; dP/dtmax and dP/dtmin, maximum and minimum of the first derivative of LV pressure over time; Tau, time constant for isovolumic relaxation; PRSW, pre-load recruitable stroke work; Ees, end-systolic elastance; and EDPVR, end-diastolic pressure volume relationship. Values are presented as mean±SEM.
  2. P<0.05 vs. saline,
  3. * P<0.05 vs. WT + DOX, and
  4. P≤0.10 vs. WT + DOX.